The dual blockade of MET and VEGFR2 signaling demonstrates pronounced inhibition on tumor growth and metastasis of hepatocellular carcinoma

[1]  R. Lencioni,et al.  A Phase I/II Multicenter Study of Single-Agent Foretinib as First-Line Therapy in Patients with Advanced Hepatocellular Carcinoma , 2016, Clinical Cancer Research.

[2]  X. Wang,et al.  GOLM1 Modulates EGFR/RTK Cell-Surface Recycling to Drive Hepatocellular Carcinoma Metastasis. , 2016, Cancer cell.

[3]  X. Bai,et al.  Inhibition of mTORC2 Induces Cell-Cycle Arrest and Enhances the Cytotoxicity of Doxorubicin by Suppressing MDR1 Expression in HCC Cells , 2015, Molecular Cancer Therapeutics.

[4]  N. Schultz,et al.  Response to MET inhibitors in patients with stage IV lung adenocarcinomas harboring MET mutations causing exon 14 skipping. , 2015, Cancer discovery.

[5]  Mark Rosenzweig,et al.  Activation of MET via diverse exon 14 splicing alterations occurs in multiple tumor types and confers clinical sensitivity to MET inhibitors. , 2015, Cancer discovery.

[6]  A. Jemal,et al.  Global cancer statistics, 2012 , 2015, CA: a cancer journal for clinicians.

[7]  Q. Ye,et al.  MicroRNA‐26a suppresses angiogenesis in human hepatocellular carcinoma by targeting hepatocyte growth factor‐cMet pathway , 2014, Hepatology.

[8]  J. Llovet,et al.  Hepatocellular Carcinoma: Reasons for Phase III Failure and Novel Perspectives on Trial Design , 2014, Clinical Cancer Research.

[9]  R. Govindan,et al.  Randomized phase II trial of Onartuzumab in combination with erlotinib in patients with advanced non-small-cell lung cancer. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  Q. Ye,et al.  MicroRNA‐26a suppresses tumor growth and metastasis of human hepatocellular carcinoma by targeting interleukin‐6‐Stat3 pathway , 2013, Hepatology.

[11]  A. Zhu,et al.  Targeting the HGF/c-MET Pathway in Hepatocellular Carcinoma , 2013, Clinical Cancer Research.

[12]  A. Sood,et al.  Resistance and escape from antiangiogenesis therapy: clinical implications and future strategies. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  R. Millikan,et al.  Neoadjuvant chemotherapy with DD-MVAC and bevacizumab in high-risk urothelial cancer: Results from a phase II trial at the M. D. Anderson Cancer Center. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  Jeffrey W. Clark,et al.  Rapid radiographic and clinical improvement after treatment of a MET-amplified recurrent glioblastoma with a mesenchymal-epithelial transition inhibitor. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  Jeffrey W. Clark,et al.  MET amplification identifies a small and aggressive subgroup of esophagogastric adenocarcinoma with evidence of responsiveness to crizotinib. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  Martin Glas,et al.  c-Met signaling induces a reprogramming network and supports the glioblastoma stem-like phenotype , 2011, Proceedings of the National Academy of Sciences.

[17]  D. Hanahan,et al.  Hallmarks of Cancer: The Next Generation , 2011, Cell.

[18]  J. Christensen,et al.  HGF/c-Met acts as an alternative angiogenic pathway in sunitinib-resistant tumors. , 2010, Cancer research.

[19]  L. Trusolino,et al.  MET signalling: principles and functions in development, organ regeneration and cancer , 2010, Nature Reviews Molecular Cell Biology.

[20]  O. Rosmorduc,et al.  Hypoxia: a link between fibrogenesis, angiogenesis, and carcinogenesis in liver disease. , 2010, Seminars in liver disease.

[21]  John M L Ebos,et al.  Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. , 2009, Cancer cell.

[22]  Masahiro Inoue,et al.  Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. , 2009, Cancer cell.

[23]  K. Hirata,et al.  Prognostic Impact of Surgical Complications and Preoperative Serum Hepatocyte Growth Factor in Hepatocellular Carcinoma Patients After Initial Hepatectomy , 2009, Journal of Gastrointestinal Surgery.

[24]  S. Paggi,et al.  Sorafenib in Advanced Hepatocellular Carcinoma , 2008 .

[25]  Joon-Oh Park,et al.  MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling , 2007, Science.

[26]  S. Thorgeirsson,et al.  Met-regulated expression signature defines a subset of human hepatocellular carcinomas with poor prognosis and aggressive phenotype. , 2006, The Journal of clinical investigation.

[27]  P. Tangkijvanich,et al.  Association between serum hepatocyte growth factor and survival in untreated hepatocellular carcinoma , 2004, Journal of Gastroenterology.

[28]  Gavin Thurston,et al.  Inhibition of vascular endothelial growth factor (VEGF) signaling in cancer causes loss of endothelial fenestrations, regression of tumor vessels, and appearance of basement membrane ghosts. , 2004, The American journal of pathology.

[29]  O. Volpert,et al.  Hepatocyte growth factor/scatter factor mediates angiogenesis through positive VEGF and negative thrombospondin 1 regulation , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[30]  P. Comoglio,et al.  Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene. , 2003, Cancer cell.

[31]  E. Van Cutsem,et al.  Activity of cabozantinib (XL184) in hepatocellular carcinoma patients (pts): Results from a phase II randomized discontinuation trial (RDT). , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[32]  E. Van Cutsem,et al.  Activity of cabozantinib (XL184) in hepatocellular carcinoma: Results from a phase II randomized discontinuation trial (RDT) , 2012 .

[33]  A. Jemal,et al.  Global Cancer Statistics , 2011 .

[34]  Yoon-Koo Kang,et al.  Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. , 2009, The Lancet. Oncology.

[35]  A. Jemal,et al.  Global cancer statistics , 2011, CA: a cancer journal for clinicians.